Biyokimyasal Kemik Belirteçleri

Osteopatilerin teşhis, tedavi ve izlenmesinde radyolojik teknikler ile korole olarak kullanılmakta olan klinik öneme sahipbirçok biyokimyasal kemik belirteci bulunmaktadır. Biyokimyasal kemik belirteçleri kemik oluşum ve rezorbsiyonhızlarının göstergesi olarak kabul edilirler. Ayrıca biyokimyasal kemik belirteçleri radyolojik yöntemler ilekarşılaştırıldığında, örnek toplanmasının kolay olması, test maliyetinin düşüklüğü, uygulanabilirlik, kemik hastalıklarınınizlenmesinde kısa zaman aralıkları ile yararlanabilme ve tekrarlayabilme gibi avantajları nedeniyle de önemkazanmaktadır. Bu çalışmada osteopatilerde teşhis ve izleminde kullanılmakta olan biyokimyasal belirteçlerideğerlendirilmiştir

Biochemical Bone Markers

There are many biochemical bone markers with clinical importance that are used as a chorole with radiological techniques in the diagnosis, treatment and monitoring of osteopathies. Biochemical bone markers are considered as indicators of bone formation and resorption rates. Furthermore, when compared to radiological methods, biochemical bone markers gain importance due to their advantages such as easy sample collection, low test cost, applicability, short time intervals in monitoring bone diseases, and replicability. In this study, biochemical markers used in diagnosis and follow-up in osteopathies were evaluated

___

  • 1. Silvent J, Nassif N, Helary C, Azais T, Sire JY, and Guille MM. Collagen osteoidlike model allows kinetic gene expression studies of non-collagenous proteins in relation with mineral development to understand bone biomineralization, PLoS One. 2013; 8:e57344.
  • 2. Lopez-Larramona G, Tenias Burillo JM, and Lucendo Villarin AJ. The Association between Nutritional Screening Via The Conut Index And Bone Mineral Density In Chronic Liver Disease of Various Etiologies, Hepatol Res. 2014;
  • 3. Murtezani A, Nevzati A, Ibraimi Z, Sllamniku S, Meka VS, and Abazi N. The Effect of Land versus Aquatic Exercise Program on Bone Mineral Density and Physical Function in Postmenopausal Women with Osteoporosis: a Randomized Controlled Trial, Ortop Traumatol Rehabil. 2014;16:319-25.
  • 4. Minisola G, Iuliano A, and Prevete I. Emerging therapies for osteoporosis, Reumatismo. 2014;66:112-24.
  • 5. Wang Y, Bishop NM, Taatjes DJ, Narisawa S, Millan JL, and Palmer BM. Sexdependent, zinc-induced de-phosphorylation of phospholamban by tissue nonspecific alkaline phosphatase in the cardiac sarcomere, Am J Physiol Heart Circ Physiol. 2014;
  • 6. Liu J, Nam HK, Campbell C, Gasque KC, Millan JL, and Hatch NE. Tissuenonspecific alkaline phosphatase deficiency causes abnormal craniofacial bone development in the Alpl mouse model of infantile hypophosphatasia, Bone. 2014;67C:81-94.
  • 7. Dahlman I, Gerdhem P, and Bergstrom I. Vitamin D status and bone health in immigrant versus Swedish women during pregnancy and the post-partum period, J Musculoskelet Neuronal Interact. 2013;13:464-9.
  • 8. Gallo S, Comeau K, Sharma A, Vanstone CA, Agellon S, Mitchell J, Weiler HA, and Rodd C. Redefining normal bone and mineral clinical biochemistry reference intervals for healthy infants in Canada, Clin Biochem. 2014;
  • 9. Kumchev EP, Stanchev VL, Yaneva MP, Botushanova AD, Dimitrova RH, and Dimitrakov DJ. Assessment of serum osteocalcine level in pre-dialysis patients with chronic renal failure, Folia Med (Plovdiv). 2000;42:14-8.
  • 10. Christensen JD, Lungu AO, Cochran E, Collins MT, Gafni RI, Rother KI, Gorden P, and Brown RJ. Bone Mineral Content in Patients With Congenital Generalized Lipodystrophy Is Unaffected by Metreleptin Replacement Therapy, J Clin Endocrinol Metab. 2014;jc20141353.
  • 11. Lumachi F, Santeufemia DA, Del Conte A, Mazza F, Tozzoli R, Chiara GB, and Basso SM. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide 16 (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer, Anticancer Res. 2013;33:2593-6.
  • 12. Tokuda T, Hasegawa J, Matsuda A, and Hagino H. Bone mineral density in residents of care facilities for the aged and effect of pharmacotherapy, Yonago Acta Med, 2014;57:45-52.
  • 13. Shetty R, Nagaraja H, Jayadev C, Shivanna Y, and Kugar T. Collagen crosslinking in the management of advanced nonresolving microbial keratitis, Br J Ophthalmol, 2014;98:1033-5.
  • 14. Mertens ME, Hermann A, Buhren A, Olde-Damink L, Mockel D, Gremse F, Ehling J, Kiessling F, and Lammers T. Iron Oxide-labeled Collagen Scaffolds for Non-invasive MR Imaging in Tissue Engineering, Adv Funct Mater,. 2014;24:754-62.
  • 15. Xia S, Fan X, Huang Z, Xia L, Xiao M, Chen R, Xu Y, and Zhuo C. Dominance of CTX-M-Type Extended-Spectrum betaLactamase (ESBL)-Producing Escherichia coli Isolated from Patients with Community-Onset and Hospital-Onset Infection in China, PLoS One, 2014; 9:e100707.
  • 16. Greiner C, Cavalier E, Remy B, Gabriel A, Farnir F, Gajewski Z, and Carstanjen B. Biochemical markers of bone turnover during pregnancy in horses: a longitudinal study, Pol J Vet Sci. 2012;15:793-5.
  • 17. Anai T, Urata K, Mori A, Miyazaki F, and Okamoto S. Transient osteoporosis of the hip in pregnancy associated with generalized low bone mineral density--a case report, Gynecol Obstet Invest. 2013;76:133-8.
  • 18. Bogers SH, Rogers CW, Bolwell CF, Roe WD, Gee EK, and Mcilwraith CW. Impact of race training on volumetric bone mineral density and its spatial distribution in the distal epiphysis of the third metatarsal bone of 2-year-old horses, Vet J, 2014;
  • 19. Zhu K, Whitehouse AJ, Hart PH, Kusel M, Mountain J, Lye S, Pennell C, and Walsh JP. Maternal vitamin D status during pregnancy and bone mass in offspring at 20 years of age: a prospective cohort study, J Bone Miner Res. 2014;29:1088- 95.
  • 20. Osteoporosis drugs linked to jawbone destruction. J Calif Dent Assoc, 2014;42:435.
  • 21. Lee SY, Auh QS, Kang SK, Kim HJ, Lee JW, Noh K, Jang JH, and Kim EC. Combined effects of dentin sialoprotein and bone morphogenetic protein-2 on differentiation in human cementoblasts, Cell Tissue Res. 2014;357:119-32.
  • 22. Kovacheva M, Zepp M, Berger SM, and Berger MR. Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis, Oncotarget. 2014;
  • 23. Wisniewska K, Piorkowska A, Kasprzyk J, Bronk M, and Swiec K. Clonal distribution of bone sialoprotein-binding protein gene among Staphylococcus aureus isolates associated with bloodstream infections, Folia Microbiol (Praha). 2014;
  • 24. Graziano A, D'aquino R, Laino G, and Papaccio G. Dental pulp stem cells: a promising tool for bone regeneration, Stem Cell Rev. 2008;4:21-6.
  • 25. Chao Huang D, Fang Yang X, Ochietti B, Fadhil I, Camirand A, and Kremer R. Parathyroid hormone-related protein: potential therapeutic target for melanoma invasion and metastasis, Endocrinology, 2014; en20131803.
  • 26. Alqahtani A, Parsyan A, Payne R, and Tabah R. Parathyroid hormone levels 1 hour after thyroidectomy: an early predictor of postoperative hypocalcemia, Can J Surg. 2014;57:237-40.
  • 27. Zhang Y, Kumagai K, and Saito T. Effect of parathyroid hormone on early chondrogenic differentiation from mesenchymal stem cells, J Orthop Surg Res, 2014;9:68.
  • 28. Chung IH, Kim HJ, Chung S, and Yoo EG. Vitamin D deficiency in Korean children: prevalence, risk factors, and the relationship with parathyroid hormone levels, Ann Pediatr Endocrinol Metab. 2014;19:86-90.
  • 29. Jia HB, Ma JX, Ma XL, Yu JT, Feng R, Xu LY, Wang J, Xing D, Zhu SW, and Wang Y. Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats, Osteoporos Int. 2014;
  • 30. Katikaneni R, Ponnapakkam T, Matsushita O, Sakon J, and Gensure R. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagentargeted parathyroid hormone analog, in a non-depilated mouse model, Anticancer Drugs. 2014;25:30-8.
  • 31. Aspray TJ, Bowring C, Fraser W, Gittoes N, Javaid MK, Macdonald H, Patel S, Selby P, Tanna N, and Francis RM. National Osteoporosis Society Vitamin D Guideline Summary, Age Ageing. 2014;
  • 32. Harvey NC, Javaid MK, Inskip HM, Godfrey KM, and Cooper C. Maternal vitamin D status during pregnancy and bonemineral content in offspring, Lancet. 2013;382:766.
  • 33. O'brien KO, Donangelo CM, Ritchie LD, Gildengorin G, Abrams S, and King JC. Serum 1,25-dihydroxyvitamin D and calcium intake affect rates of bone calcium deposition during pregnancy and the early postpartum period, Am J Clin Nutr. 2012;96:64-72.
  • 34. Moller UK, Streym S, Mosekilde L, Heickendorff L, Flyvbjerg A, Frystyk J, Jensen LT, and Rejnmark L. Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study, Osteoporos Int. 2013;24:1307-20.
  • 35. Binkley N, Bone H, Gilligan JP, and Krause DS. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial, Osteoporos Int, 2014;
  • 36. Yun H, Delzell E, Saag KG, Kilgore ML, Morrisey MA, Muntner P, Matthews R, Guo L, Wright N, Smith W, Colon-Emeric C, O'connor CM, Lyles KW, and Curtis JR. Fractures and mortality in relation to different osteoporosis treatments, Clin Exp Rheumatol. 2014;
  • 37. Rosa BV, Blair HT, Vickers MH, Dittmer KE, Morel PC, Knight CG, and Firth EC. Moderate exercise during pregnancy in Wistar rats alters bone and body composition of the adult offspring in a sex-dependent manner, PLoS One. 2013;8:e82378.